Immunic (NASDAQ:IMUX) (NASDAQ: IMUX) is a clinical‐stage biopharmaceutical company focused on developing oral therapies to treat chronic inflammatory and autoimmune diseases. Founded in 2012, the company is engaged in the research and development of small‐molecule compounds designed to modulate immune pathways. Immunic’s scientific approach seeks to offer patients more convenient, targeted treatment options compared with injectable biologics.
The company’s lead program, vidofludimus calcium (IMU-838), is being evaluated in multiple indications including ulcerative colitis, primary sclerosing cholangitis and relapsing forms of multiple sclerosis. Additional pipeline candidates include IMU-935, aimed at addressing immune‐mediated dermatological and systemic diseases such as psoriasis and systemic lupus erythematosus, and IMU-856, which targets gastrointestinal barrier function for conditions like Crohn’s disease.
Headquartered in New York with a research and development site in Martinsried, Germany, Immunic conducts clinical trials across North America and Europe. The company collaborates with academic institutions and contract research organizations to advance its programs through Phase 2 and Phase 3 studies, while engaging with regulatory authorities to align on development paths and potential market approvals.
Immunic is led by a management team with extensive experience in immunology, clinical development and pharmacology. Guided by a board of directors with backgrounds in biotechnology and pharmaceutical commercialization, the company aims to leverage its specialized expertise to bring innovative, orally administered treatments to patients suffering from debilitating inflammatory diseases.
